Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocare

This article was originally published in The Gray Sheet

Executive Summary

Completes $5 mil. convertible debenture financing with an option for an additional $5 mil. investment by the same institutional investor, the firm reports. Proceeds will be used to support an "aggressive" launch of the firm's Cryocare technology for prostate cancer in conjunction with the July 1 start of a Medicare national coverage policy providing reimbursement of cryosurgical treatments for prostate cancer ("The Gray Sheet" Feb. 15, p. 15). The system, which uses extremly cold temperatures to freeze and destroy selected tissue, was 510(k)-cleared in mid-1995 for ablation of the entire prostate to treat prostate cancer, and in April 1998 for treatment of benign prostatic hyperplasia ("The Gray Sheet" May 4, 1998, In Brief). A portion of the proceeds also will be used to support the upcoming international launch of the Horizon prostatic stent for acute urinary retention. CIBC Oppenheimer acted as placement agent for the transaction
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel